menu
    • menu
    [{"orgOrder":0,"company":"VivaVision","sponsor":"Everads Therapy","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VivaVision \/ Everads Therapy","highestDevelopmentStatusID":"2","companyTruncated":"VivaVision \/ Everads Therapy"},{"orgOrder":0,"company":"VivaVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VVN461","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VivaVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Inapplicable"},{"orgOrder":0,"company":"VivaVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VVN539","moa":"ROCK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution\/Drops","sponsorNew":"VivaVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Inapplicable"},{"orgOrder":0,"company":"VivaVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VVN461","moa":"JAK1\/TYK2","graph1":"Immunology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"VivaVision \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by VivaVision

    Menu

    VivaVision

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VivaVision

                            China arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            VivaVision

                            China arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VVN461

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VivaVision Finds Positive Phase 2 Results for VVN461 in Post-Cataract Inflammation

                            Details : VVN461 is a potent non-steroidal dual JAK1/TYK2 immunomodulator, being investigated for the treatment of post-operative inflammation following cataract surgery.

                            Product Name : VVN461

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 04, 2024

                            Lead Product(s) : VVN461

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            VivaVision

                            China arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            VivaVision

                            China arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VVN461

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VivaVision Ph 2 of VVN461 Shows Positive Results for Post-Cataract Surgery Inflammation

                            Details : VVN461 is a potent non-steroidal dual JAK1/TYK2 immunomodulator, which is currently being evaluated for the treatment of post-operative inflammation following cataract surgery.

                            Product Name : VVN461

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 12, 2024

                            Lead Product(s) : VVN461

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            VivaVision

                            China arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            VivaVision

                            China arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery

                            Sponsor : Everads Therapy

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases

                            Details :

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery

                            Sponsor : Everads Therapy

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            VivaVision

                            China arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            VivaVision

                            China arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VVN539

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VVN539 Met Primary Study Endpoints in US Phase IIa Clinical Study for The Treatment of Glaucoma

                            Details : VVN539 Ophthalmic Solution is a first-in-class small molecule for the treatment of glaucoma. It acts directly at trabecular meshwork, increases the outflow of aqueous humor for the treatment of with primary open angle glaucoma.

                            Product Name : VVN539

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 06, 2023

                            Lead Product(s) : VVN539

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth